<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-five patients with high-risk <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> (32 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and 13 high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>) were treated with fludarabine, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, and G-CSF (FLAG-IDA) </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-four (53%) patients achieved complete remission (CR), and five (11%) partial remission </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> predominantly with pulmonary involvement was the most common regimen-related toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>Mucositis (15 patients) and pulmonary toxicity (19 patients) were the most frequently observed non-hematologic side effects </plain></SENT>
<SENT sid="4" pm="."><plain>There were four early <z:hpo ids='HP_0011420'>deaths</z:hpo> and 12 patients presented with resistant disease </plain></SENT>
<SENT sid="5" pm="."><plain>Overall survival (OS) at 12 months was 40% </plain></SENT>
<SENT sid="6" pm="."><plain>The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> with acceptable toxicity </plain></SENT>
</text></document>